Azithromycin for severe COVID-19

Catherine E Oldenburg¹, Thuy Doan²

Affiliations

¹ Francis I Proctor Foundation, University of California, San Francisco, CA 94158, USA; Department of Ophthalmology, University of California, San Francisco, CA 94158, USA; Department of Epidemiology and Biostatistics, University of California, San Francisco, CA 94158, USA. Electronic address: catherine.oldenburg@ucsf.edu.
² Francis I Proctor Foundation, University of California, San Francisco, CA 94158, USA; Department of Ophthalmology, University of California, San Francisco, CA 94158, USA.

PMID: 32896293
PMCID: PMC7833672
DOI: 10.1016/S0140-6736(20)31863-8

Comment

Azithromycin for severe COVID-19

Catherine E Oldenburg et al. Lancet. 2020.

. 2020 Oct 3;396(10256):936-937.

doi: 10.1016/S0140-6736(20)31863-8. Epub 2020 Sep 5.

Authors

Catherine E Oldenburg¹, Thuy Doan²

Affiliations

¹ Francis I Proctor Foundation, University of California, San Francisco, CA 94158, USA; Department of Ophthalmology, University of California, San Francisco, CA 94158, USA; Department of Epidemiology and Biostatistics, University of California, San Francisco, CA 94158, USA. Electronic address: catherine.oldenburg@ucsf.edu.
² Francis I Proctor Foundation, University of California, San Francisco, CA 94158, USA; Department of Ophthalmology, University of California, San Francisco, CA 94158, USA.

PMID: 32896293
PMCID: PMC7833672
DOI: 10.1016/S0140-6736(20)31863-8

No abstract available

PubMed Disclaimer

Figures

See this image and copyright information in PMC

Comment on

Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial.
Furtado RHM, Berwanger O, Fonseca HA, Corrêa TD, Ferraz LR, Lapa MG, Zampieri FG, Veiga VC, Azevedo LCP, Rosa RG, Lopes RD, Avezum A, Manoel ALO, Piza FMT, Martins PA, Lisboa TC, Pereira AJ, Olivato GB, Dantas VCS, Milan EP, Gebara OCE, Amazonas RB, Oliveira MB, Soares RVP, Moia DDF, Piano LPA, Castilho K, Momesso RGRAP, Schettino GPP, Rizzo LV, Neto AS, Machado FR, Cavalcanti AB; COALITION COVID-19 Brazil II Investigators. Furtado RHM, et al. Lancet. 2020 Oct 3;396(10256):959-967. doi: 10.1016/S0140-6736(20)31862-6. Epub 2020 Sep 5. Lancet. 2020. PMID: 32896292 Free PMC article. Clinical Trial.

References

1. Tang W, Cao Z, Han M. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;369 - PMC - PubMed
1. Skipper CP, Pastick KA, Engen NW. Hydroxychloroquine in nonhospitalized adults with early COVID-19. Ann Intern Med. 2020 doi: 10.7326/M20-4207. published online July 16. - DOI - PubMed
1. Cheng MP, Labar D, Lother SA. A randomized trial of hydroxychloroquine as postexposure prophylaxis for COVID-19. N Engl J Med. 2020;383:517–525. - PMC - PubMed
1. Retallack H, Di E, Arias C. Zika virus cell tropism in the developing human brain and inhibition by azithromycin. Proc Natl Acad Sci USA. 2016;113:14408–14413. - PMC - PubMed
1. Schögler A, Kopf BS, Edwards MR. Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells. Eur Respir J. 2015;45:428–439. - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Azithromycin for severe COVID-19

Affiliations

Azithromycin for severe COVID-19

Authors

Affiliations

Figures

Comment on

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources